AI English summary of an SEC filing — figures as filed
Zimmer Biomet ZBHZimmer Biomet said it appointed Kevin Thornal to the newly created position of Group President, Global Businesses and the Americas, effective on July 1, 2025. The company said the announcement was made on May 27, 2025.
Key points
AI summaryZimmer Biomet said it appointed Kevin Thornal to the newly created position of Group President, Global Businesses and the Americas, effective on July 1, 2025. The company said the announcement was made on May 27, 2025.
The company said Thornal served as President and Chief Executive Officer of Nevro Corp. from April 2023 until Globus Medical, Inc. completed its acquisition of Nevro Corp. in April 2025. Mark Bezjak, President, Americas, will keep that title but will cease to be an executive officer when Thornal joins the company.
Zimmer Biomet said the offer letter sets Thornal's initial annual base salary at $850,000 and his target annual bonus for 2025 at 100% of base salary, prorated for a partial year of service in 2025. The RSUs and PRSUs each have a grant date fair value of approximately $2,650,000, and the RSUs vest ratably over the first 3 anniversaries of the grant date.
Zimmer Biomet said the Change in Control Severance Agreement with Thornal provides a lump sum payment of 2 times the sum of his base salary and target annual bonus if his employment is terminated during the agreement term after a change in control, other than for cause, death or resignation without good reason. The agreement does not provide for any tax gross-up, and all payments are subject to Thornal signing a general release of claims.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Kevin Thornal Appointed Group President, Global Businesses and the Americas
Zimmer Biomet said it appointed Kevin Thornal to the newly created position of Group President, Global Businesses and the Americas, effective on July 1, 2025. The company said the announcement was made on May 27, 2025.
Source · Based on the filing body and exhibits
Thornal's Background and Mark Bezjak's Role Change
The company said Thornal served as President and Chief Executive Officer of Nevro Corp. from April 2023 until Globus Medical, Inc. completed its acquisition of Nevro Corp. in April 2025. Mark Bezjak, President, Americas, will keep that title but will cease to be an executive officer when Thornal joins the company.
Source · Based on the filing body and exhibits
Offer Letter Terms for Salary, Bonus and Equity Awards
Zimmer Biomet said the offer letter sets Thornal's initial annual base salary at $850,000 and his target annual bonus for 2025 at 100% of base salary, prorated for a partial year of service in 2025. The RSUs and PRSUs each have a grant date fair value of approximately $2,650,000, and the RSUs vest ratably over the first 3 anniversaries of the grant date.
Source · Based on the filing body and exhibits
Payment Terms Under the Change in Control Severance Agreement
Zimmer Biomet said the Change in Control Severance Agreement with Thornal provides a lump sum payment of 2 times the sum of his base salary and target annual bonus if his employment is terminated during the agreement term after a change in control, other than for cause, death or resignation without good reason. The agreement does not provide for any tax gross-up, and all payments are subject to Thornal signing a general release of claims.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…